Clinical trial
A Phase I Study in Patients Treated With MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
NCT01770353 is registered in ClinicalTrials.gov with Ipsen as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Study in Patients Treated With MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
- Lead sponsor
- Ipsen
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- November 30, 2012
- Completion date
- October 2, 2018
- Enrollment
- 45 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.
er/pr positive breast cancer, metastatic breast cancer with active brain metastasis, solid tumors, triple negative breast cancer